1/6
06:45 am
mrk
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
12/31
07:29 am
mrk
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79% [Yahoo! Finance]
Low
Report
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79% [Yahoo! Finance]
12/30
07:16 pm
mrk
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know [Yahoo! Finance]
Low
Report
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know [Yahoo! Finance]
12/27
12:45 pm
mrk
U.S. FDA approves injectable version of cancer drug from Bristol Myers Squibb [Globe and Mail, The (Toronto, Canada)]
Low
Report
U.S. FDA approves injectable version of cancer drug from Bristol Myers Squibb [Globe and Mail, The (Toronto, Canada)]
12/27
07:34 am
mrk
Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals? [Yahoo! Finance]
Low
Report
Will Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Prove Temporary Given Strong Fundamentals? [Yahoo! Finance]
12/27
04:26 am
mrk
Animal Parasiticides Market Worth $15.83 Billion by 2032: An Analysis of Revenue and % Shares by Type, Animal, End User, Country, and Company [Yahoo! Finance]
Low
Report
Animal Parasiticides Market Worth $15.83 Billion by 2032: An Analysis of Revenue and % Shares by Type, Animal, End User, Country, and Company [Yahoo! Finance]
12/26
10:03 am
mrk
2 Reasons to Sell Merck Stock and 1 Reason to Buy [Yahoo! Finance]
Low
Report
2 Reasons to Sell Merck Stock and 1 Reason to Buy [Yahoo! Finance]
12/24
07:41 pm
mrk
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing [Yahoo! Finance]
Low
Report
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing [Yahoo! Finance]
12/23
09:01 am
mrk
https://seekingalpha.com/article/4745912-merck-low-hanging-fruit-to-pick [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4745912-merck-low-hanging-fruit-to-pick [Seeking Alpha]
12/20
11:27 am
mrk
More on MRK's HIV-1 Program [Yahoo! Finance]
Neutral
Report
More on MRK's HIV-1 Program [Yahoo! Finance]
12/20
10:29 am
mrk
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
Low
Report
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
12/20
09:57 am
mrk
BMO cuts rating on Merck and Biogen, on lack of near term catalyst [Yahoo! Finance]
Low
Report
BMO cuts rating on Merck and Biogen, on lack of near term catalyst [Yahoo! Finance]
12/20
09:22 am
mrk
Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain [Yahoo! Finance]
Low
Report
Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain [Yahoo! Finance]
12/20
09:22 am
mrk
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals [Yahoo! Finance]
Low
Report
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals [Yahoo! Finance]
12/20
08:09 am
mrk
Merck & Co., Inc. (NYSE: MRK) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $105.00 price target on the stock, down previously from $136.00.
Low
Report
Merck & Co., Inc. (NYSE: MRK) was downgraded by analysts at BMO Capital Markets from an "outperform" rating to a "market perform" rating. They now have a $105.00 price target on the stock, down previously from $136.00.
12/20
07:59 am
mrk
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks [Yahoo! Finance]
Low
Report
Want to Collect a Dividend Every Month? Invest in These 3 High-Yielding Income Stocks [Yahoo! Finance]
12/20
07:27 am
mrk
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? [Yahoo! Finance]
Low
Report
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? [Yahoo! Finance]
12/20
06:52 am
mrk
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody [Yahoo! Finance]
Low
Report
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody [Yahoo! Finance]
12/20
06:52 am
mrk
Is Moderna Stock a Buy? [Yahoo! Finance]
Low
Report
Is Moderna Stock a Buy? [Yahoo! Finance]
12/20
06:45 am
mrk
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
Low
Report
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
12/19
10:32 am
mrk
Cancer Vaccines Market to Hit USD 20.47 Billion by 2032 with 8.6% CAGR | MarketsandMarkets™. [Yahoo! Finance]
Low
Report
Cancer Vaccines Market to Hit USD 20.47 Billion by 2032 with 8.6% CAGR | MarketsandMarkets™. [Yahoo! Finance]
12/19
10:12 am
mrk
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug [Yahoo! Finance]
Low
Report
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug [Yahoo! Finance]
12/19
08:15 am
mrk
Merck's RSV antibody could soon paddle into the rough waters of a crowded market [Yahoo! Finance]
Low
Report
Merck's RSV antibody could soon paddle into the rough waters of a crowded market [Yahoo! Finance]
12/19
07:02 am
mrk
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection [Yahoo!
Low
Report
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection [Yahoo!
12/19
06:45 am
mrk
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
Low
Report
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection